US Patent 10,034,938: What the Claims Actually Cover and How Crowded the Landscape Is
US Patent 10,034,938 is directed to combination immunotherapy for advanced melanoma (stages IIIb to IV) using an oncolytic herpes simplex virus engineered to be ICP34.5- and ICP47-deficient and to express human GM-CSF, in combination with an immune checkpoint inhibitor that is an anti-PD-1 or anti-CTLA-4 antibody. The strongest claim set ties the engineered HSV to T-VEC (talimogene laherparepvec)-type genetics and treatment patterns, and locks the immunotherapy partner to specific commercially relevant checkpoint antibodies, with dosing and sequencing language in dependent claims.
What are the core independent claim themes?
Claim 1: method with engineered HSV + anti-PD-1/anti-CTLA-4
Claim 1 is the broad method claim. It requires four technical elements:
- Patient population: “stages IIIb to IV melanoma”
- Immune checkpoint inhibitor: an anti-PD-1 antibody or anti-CTLA-4 antibody
- Herpes simplex virus engineering:
- herpes simplex virus lacks a functional ICP34.5 gene
- herpes simplex virus lacks a functional ICP47 gene
- herpes simplex virus comprises a gene encoding human GM-CSF
- Administration concept: HSV is administered as part of the combination (sequencing is added in dependent claims)
Claim 1 is broad on the checkpoint side (covers both PD-1 and CTLA-4 antibodies) and broad on administration (no dosing schedule in claim 1 itself).
Claim 2: kit containing engineered HSV + instructions for combination treatment
Claim 2 mirrors Claim 1 in kit form. It requires:
- A HSV with ICP34.5- / ICP47- / GM-CSF profile
- A package insert or label with directions to treat stages IIIb to IV melanoma using:
- the engineered HSV + an anti-PD-1 or anti-CTLA-4 antibody
Claim 2 is important because kit claims can be used to control distribution even when method practice by a clinic is less cleanly attributable.
What do the dependent claims narrow to?
Checkpoint antibody identity and antibody class
- Claim 4: checkpoint antibodies are IgG
- Claim 5: anti-CTLA-4 is ipilimumab
- Claim 8: anti-PD-1 antibody is selected from nivolumab, lambrolizumab, CT-011, AMP-224
- Claims 14, 17, 18: repeat IgG and checkpoint choice in kit context
This means the patent set does not just cover “anti-PD-1/anti-CTLA-4” generically. It also includes explicit enumerations of commercial/late-stage candidates and clinical-stage molecules.
HSV identity (T-VEC lock-in)
- Claim 7: HSV is talimogene laherparepvec
- Claims 11 and 12: HSV is talimogene laherparepvec and anti-CTLA-4 is ipilimumab
- Claims 16 and 18: T-VEC + anti-PD-1 selected from lambrolizumab or nivolumab
- Claims 13 and 9: specify tumor site injection targets (injectable cutaneous, subcutaneous, and nodal tumors)
This structure creates two layers:
- A chemistry/genetic specification layer (ICP34.5-/ICP47-/GM-CSF) that can cover engineered HSV variants meeting the profile.
- A product identity layer (T-VEC) that can make enforcement easier by tying to a known commercial product.
Sequencing requirement
- Claim 6: HSV precedes the administration of the anti-PD-1 or anti-CTLA-4 antibody
Sequencing language can materially affect infringement analysis against protocols that administer checkpoint first, or that administer concurrently.
Dosing and schedule lock-in (the high-friction claim)
Claim 3 is the most operationally specific claim. It requires:
- HSV: Talimogene laherparepvec-type genetics (ICP34.5-/ICP47-/GM-CSF) and includes:
- Intratumoral injection
- Dose schedule:
- up to 4.0 mL at 10^6 PFU/mL at day 1 of week 1
- up to 4.0 mL at 10^8 PFU/mL at day 1 of week 4
- then every 2 weeks thereafter until complete response
- Anti-CTLA-4: 3 mg/kg IV every 3 weeks, for 4 infusions
- starting after the third dose of HSV
Claim 9 is a kit analog that repeats substantially the same operational dosing and injection-target language, plus the CTLA-4 schedule.
Manufacturing claim
- Claim 10: “method of manufacturing the kit of claim 2”
A manufacturing claim can support downstream control (labeling/packaging/combination preparation) but it also tends to be narrower in practice because actual “manufacturing of a kit” is fact-dependent.
What is the claim coverage in plain technical terms?
US 10,034,938’s coverage centers on a very particular HSV engineering profile that is widely associated with T‑VEC. The checkpoint combination is framed to include anti-PD-1 or anti-CTLA-4, then dependent claims narrow to:
- ipilimumab (anti-CTLA-4)
- nivolumab/lambrolizumab (anti-PD-1) and also enumerated clinical candidates (CT-011, AMP-224)
The enforcement posture is strongest where all of these elements align:
- patient population: stage IIIb to IV melanoma
- HSV: ICP34.5-, ICP47- and GM-CSF
- treatment structure: HSV-first sequencing and/or dosing schedule
- checkpoint pairing: ipilimumab or the enumerated PD-1 antibodies
How does the dependent claim scaffold map to likely infringement scenarios?
Scenario A: clinic uses T-VEC + ipilimumab with a similar sequence
- High match to Claims 1, 6, 7, 11, 12, 3 (depending on whether full dosing language is used)
- Moderate match to Claims 2, 9 if kit labeling matches and includes the specified schedule
Scenario B: clinic uses HSV engineered differently from ICP34.5/ICP47 deletion
- Low match unless the HSV still lacks functional ICP34.5 and ICP47 and includes human GM-CSF
Scenario C: HSV injection site differs (non-injectable or different lesion classes)
- Claims 13 and 9 specify injectable cutaneous/subcutaneous/nodal tumors, so variants could avoid those dependent claims while still potentially triggering broader claim 1/2.
Scenario D: PD-1 antibody partner is an unlisted anti-PD-1
- Claim 1/2 still cover “anti-PD-1 antibody” in general.
- Avoidance is possible if the partner is not a PD-1 antibody (for example, an antibody that targets a different checkpoint).
Where is the patent landscape most crowded? (Freedom-to-operate pressure points)
The landscape for T‑VEC-like oncolytic HSV plus checkpoint blockade is crowded because:
- T‑VEC’s genetic deletions (ICP34.5 and ICP47) and GM‑CSF expression are a known oncolytic HSV platform.
- Checkpoint combinations for melanoma are widely claimed across multiple patent families (each partner drug has its own IP around dosing, indications, combinations, and formulations).
- Kit and label claims like Claims 2 and 9 can extend control over distribution and use instructions.
Key crowding vectors
- HSV platform IP: genetic-engineering claims and method claims tied to ICP34.5/ICP47 deletion and GM‑CSF expression.
- Combination immunotherapy IP: combination method claims for melanoma involving checkpoint antibodies and oncolytic HSVs.
- Product identity: where independent claims are generic but dependent claims point to T‑VEC, commercial enforcement becomes cleaner.
- Dose/schedule and sequencing: Claimed timing can carve out protocol-specific exclusivities and create inter-protocol infringement ambiguity.
Critical analysis: where the claims are strong versus where they are vulnerable
Strengths
- Genetic definition is crisp: “lacks functional ICP34.5,” “lacks functional ICP47,” and “comprises GM‑CSF.” This is concrete and testable in HSV characterization.
- Checkpoint scope is broad in independent claims: Claim 1 covers anti-PD-1 or anti-CTLA-4 without naming a single antibody.
- Operational specificity exists: Claim 3 and Claim 9 lock dosing and scheduling for HSV and ipilimumab, which increases enforceability against clinics following the specific regimen.
- Product tie-in: dependent claims that name T‑VEC reduce ambiguity for enforcement and licensing.
Vulnerabilities
- Biological equivalence risk: if an HSV is engineered to achieve similar functional outcomes but does not literally lack functional ICP34.5/ICP47, claim 1 may be avoided. This creates a design-around path based on HSV genetics.
- Protocol dependence: Claim 3 uses explicit dosing units, injection timing, and “until complete response.” Even if a clinic uses the same concept, deviations in dosing schedule or starting infusion timing can weaken infringement of the dependent claims.
- Indication boundaries: the claims are limited to stages IIIb to IV melanoma. Using similar therapies in earlier stages or in different melanoma populations can avoid these claims.
- Antibody substitution risk: Claim 5 is ipilimumab and Claim 8 is a list of PD-1 antibodies. Even though claim 1 still covers “anti-PD-1,” other claim sets for those specific antibodies may be more heavily litigated in the broader landscape, changing practical risk allocation.
How investors should treat the patent in a diligence model
US 10,034,938 functions as a combination-control patent built on a platform HSV and paired with checkpoint immunotherapy. Its value depends on:
- whether competitors’ HSV constructs match the ICP34.5/ICP47/GM‑CSF profile, and
- whether competitors’ combination protocols match:
- HSV-first sequencing (Claim 6),
- ipilimumab dosing/schedule (Claim 3),
- and kit labeling directions (Claims 2 and 9).
A realistic diligence conclusion is that the patent creates high licensing friction for any program that intends to run T‑VEC-like HSV with checkpoint inhibitors in stage IIIb to IV melanoma using a similar regimen.
Claim-to-landscape pressure map
| Claim element |
Enforceability lever |
Common design-around vector |
| ICP34.5 deletion (no functional ICP34.5) |
Testable genetic requirement |
Alternative HSV engineering that alters ICP34.5 status |
| ICP47 deletion (no functional ICP47) |
Testable genetic requirement |
Alternative ICP47 modification |
| GM-CSF expression |
Testable transgene requirement |
Different cytokine payload or expression pattern |
| Anti-PD-1 or anti-CTLA-4 scope |
Broad independent claim |
Use non-PD-1/non-CTLA-4 checkpoint mechanism |
| Stage IIIb to IV restriction |
Limits indication |
Use in other melanoma stages/populations |
| Sequencing (HSV precedes) |
Protocol-specific |
Administer checkpoint before or concurrently |
| Dose schedule and “until complete response” |
Protocol-specific |
Deviate dosing frequency or start time |
Key Takeaways
- US 10,034,938 claims a method and kit for stage IIIb to IV melanoma using an HSV that is ICP34.5- and ICP47-deficient and expresses human GM-CSF, combined with anti-PD-1 or anti-CTLA-4 antibodies.
- The patent’s practical strength comes from dependent claims that name T‑VEC and ipilimumab, and from Claim 3/9 that recite a specific intratumoral HSV dosing schedule and ipilimumab IV schedule with sequencing logic.
- Freedom-to-operate risk concentrates on programs that use:
- T‑VEC-like genetics (or literal equivalents that meet the “functional” deletion criteria), and
- checkpoint combination protocols that preserve the HSV-first and regimen timing elements.
FAQs
1) Does Claim 1 require ipilimumab?
No. Claim 1 covers an anti-PD-1 antibody or an anti-CTLA-4 antibody. Ipilimumab is specified in Claim 5 and in T‑VEC + ipilimumab dependent claims.
2) Is T‑VEC required for infringement?
Not for Claim 1, which is defined by HSV genetics (ICP34.5/ICP47/GM‑CSF). T‑VEC appears in dependent claims like Claim 7 and Claims 11-13, 16, 18.
3) Which claim is most operationally constraining?
Claim 3. It recites intratumoral dosing volumes, PFU concentrations by week, dosing frequency, and the ipilimumab schedule and its start relative to HSV dose number.
4) Are kit claims part of the enforcement strategy?
Yes. Claim 2 and dependent Claim 9 cover a kit with label/package directions to treat stage IIIb to IV melanoma using the combination.
5) What is the main design-around path suggested by the claim language?
Alter the HSV so it does not meet the strict engineering requirements (functional ICP34.5 or functional ICP47) or swap the checkpoint mechanism away from anti-PD-1/anti-CTLA-4, or change regimen timing so dependent schedule/sequencing claims are not met.
References
[1] US Patent 10,034,938. (n.d.). Patent claims text as provided in prompt.
